|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor trametinib has shown promising therapeutic effects on melanoma, but its efficacy on colorectal cancer (CRC) is limited.
|
28756770 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In patients with BRAF-mutated melanoma specific inhibitors of BRAF<sup>V600E</sup> and MEK1/2 frequently induce initial tumor reduction, frequently followed by relapse.
|
28720543 |
2017 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored.
|
29483645 |
2018 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
|
28112278 |
2016 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, recently identified ERK1/2-inducing mutations in MEK1 and MEK2 (MEK1/2) MAPK genes in melanoma confer resistance to emerging therapeutic MEK inhibitors, underscoring the challenges facing direct kinase inhibition in cancer.
|
23603816 |
2013 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%.
|
22197931 |
2011 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FABP7 mRNA and protein level is down-regulated following treatment of melanoma cell lines with a PKC activator (PMA) or MEK1 inhibitor (PD98059).
|
18826602 |
2008 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops.
|
31727888 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma.
|
30819666 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Coupling MEK1/2 inhibitors with B-Raf inhibitors is more effective in treating such melanomas and dual therapy is now the standard of care.
|
30118796 |
2018 |
|
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types.
|
16170021 |
2005 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
It inhibited colorectal cancer and melanoma cell proliferation much more effectively than its negative control MS432N (<b>24</b>), and its effect was phenocopied by MEK1/2 knockdown.
|
31730343 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation.
|
31129802 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our data indicate that preexisting MEK1(P124) mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of patients with BRAF-mutant melanoma likely to benefit from combination therapies involving MEK or ERK inhibitors.
|
25370473 |
2015 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that melanoma cell integrin alphav was required for MAPK kinase (MEK) 1 and extracellular signal-regulated kinase (ERK)1/2 activity in 3D-collagen, whereas inhibition of MEK1 activity induced apoptosis.
|
15557124 |
2004 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma.
|
22588879 |
2012 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.
|
28387310 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consistent with these observations, pharmacological inhibition of BRAF(V600E) or MEK1/2 in human melanoma cells (using PLX4720 and CI-1040 respectively) led to a striking elevation of BIM expression.
|
18715233 |
2008 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
|
25452114 |
2014 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This MEK1(T55delins) (RT) mutation could be traced back to a fraction of the pre-treatment lesion and not only provided protection against vemurafenib but also promoted local invasion of transplanted melanomas.
|
26105199 |
2015 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer.
|
19411838 |
2009 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanoma.
|
30956763 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.
|
24448821 |
2014 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma.
|
28919996 |
2017 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, these pathways provide a way to activate MAPK signaling downstream of BRAF and MEK1 inhibitors, which are commonly used to treat melanoma.
|
30543563 |
2019 |